Medication info
Yesome Tablet 20 mg (Esomeprazole Magnesium Trihydrate)

Yesome Tablet 20 mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Trihydrate›22.3mg / 1 tablet
Manufacturer / importer
Korea Pavis Pharmaceutical Co., Ltd.
Appearance
Pale pink round film-coated tablet
Packaging
28 tablets (14 tablets/PTP) x 2
Approval status
Active

MFDS item code 201507371 · Approved 2015.10.26 · Insurance code 621802760

Summary

Main use
Treatment and prevention of gastroesophageal reflux disease, gastrointestinal disorders (ulcers, pain, etc.), and Zollinger-Ellison syndrome
Who uses it
Adults · Children
Adult dosage
This medicine should be swallowed with a liquid such as water and should not be chewed or crushed. Adults Gastroesophageal reflux disease (GERD) Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist may take it for an additional 4 weeks. Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily. Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. Once symptoms have resolved, subsequent recurring symptoms may be controlled with 20 mg once daily. In adults, 20 mg may be taken once daily as needed. As-needed use to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. Combination therapy with antibiotics for eradication of Helicobacter pylori: This medicine 20 mg is administered concomitantly with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, heartburn) associated with nonsteroidal anti-inflammatory drug (nonselective or selective COX-2) use: 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. Clinical studies exceeding 4 weeks have not been conducted. Patients requiring continuous nonsteroidal anti-inflammatory drug use Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment duration is 4∼8 weeks. Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. Treatment of Zollinger-Ellison syndrome: The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses exceeding 80 mg per day should be divided into 2 doses. Maintenance therapy after induction of prevention of rebleeding from gastric or duodenal ulcers by intravenous administration: After induction of prevention of rebleeding from gastric or duodenal ulcers by intravenous administration, administer 40 mg once daily for 4 weeks. Renal impairment: No dosage adjustment is necessary. Use with caution because there is limited experience administering this medicine to patients with severe renal impairment. Hepatic impairment: No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. Elderly patients: No dosage adjustment is necessary.
Children's dosage
Adolescents aged 12 years or older Gastroesophageal reflux disease (GERD) Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist may take it for an additional 4 weeks. Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. Once symptoms have resolved, subsequent recurring symptoms may be controlled with 20 mg once daily. In adults, 20 mg may be taken once daily as needed. As-needed use to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. Children under 12 years of age There is no experience administering this medicine to children under 12 years of age.

Ingredients

Manufacturer
Korea Pavis Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment and prevention of gastroesophageal reflux disease, gastrointestinal disorders (ulcers, pain, etc.), and Zollinger-Ellison syndrome

  • Erosive esophagitis
  • esophagitis
  • symptoms of gastroesophageal reflux disease
  • Helicobacter pylori positive duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal pain
  • upper gastrointestinal discomfort
  • upper gastrointestinal burning sensation
  • gastric ulcers
  • duodenal ulcers
  • Zollinger-Ellison syndrome
  • rebleeding from gastric ulcers
View approved original text

This medication is used as maintenance therapy for the treatment and prevention of recurrence of erosive esophagitis related to gastroesophageal reflux disease. It is also utilized in antibiotic combination therapy for the treatment and prevention of recurrence of duodenal ulcers and peptic ulcers caused by Helicobacter pylori infection. Furthermore, it is effective not only for treating upper gastrointestinal symptoms that arise from the use of non-steroidal anti-inflammatory drugs but also for treating gastric ulcers and preventing ulcers in patients receiving long-term non-steroidal anti-inflammatory drug treatment. Additionally, it is used for the treatment of Zollinger-Ellison syndrome and for preventive maintenance therapy against rebleeding in gastric and duodenal ulcers. Collectively, it improves various ulcer and inflammatory symptoms related to gastrointestinal diseases.

Dosage and Administration

Adult dosage

This medicine should be swallowed with a liquid such as water and should not be chewed or crushed. Adults Gastroesophageal reflux disease (GERD) Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist may take it for an additional 4 weeks. Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily. Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. Once symptoms have resolved, subsequent recurring symptoms may be controlled with 20 mg once daily. In adults, 20 mg may be taken once daily as needed. As-needed use to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. Combination therapy with antibiotics for eradication of Helicobacter pylori: This medicine 20 mg is administered concomitantly with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, heartburn) associated with nonsteroidal anti-inflammatory drug (nonselective or selective COX-2) use: 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. Clinical studies exceeding 4 weeks have not been conducted. Patients requiring continuous nonsteroidal anti-inflammatory drug use Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment duration is 4∼8 weeks. Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. Treatment of Zollinger-Ellison syndrome: The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses exceeding 80 mg per day should be divided into 2 doses. Maintenance therapy after induction of prevention of rebleeding from gastric or duodenal ulcers by intravenous administration: After induction of prevention of rebleeding from gastric or duodenal ulcers by intravenous administration, administer 40 mg once daily for 4 weeks. Renal impairment: No dosage adjustment is necessary. Use with caution because there is limited experience administering this medicine to patients with severe renal impairment. Hepatic impairment: No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. Elderly patients: No dosage adjustment is necessary.

Children's dosage

Adolescents aged 12 years or older Gastroesophageal reflux disease (GERD) Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist may take it for an additional 4 weeks. Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. Once symptoms have resolved, subsequent recurring symptoms may be controlled with 20 mg once daily. In adults, 20 mg may be taken once daily as needed. As-needed use to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. Children under 12 years of age There is no experience administering this medicine to children under 12 years of age.

Precautions

This medication should not be administered to certain patients. Patients with a history of allergy or hypersensitivity to this drug or its components should not use it. Additionally, patients taking certain antibiotics or antiviral agents, nursing mothers, and patients with a history of myocardial infarction should not use this medication. This medication contains the dye Yellow No. 4, and patients allergic or sensitive to this ingredient should use it carefully. Various adverse reactions may occur with this medication. Gastrointestinal symptoms such as headaches, abdominal pain, diarrhea, nausea, and vomiting are common, and occasionally neurological symptoms such as insomnia, dizziness, and mental confusion may also occur. Rarely, serious side effects such as blood abnormalities, liver function abnormalities, skin rashes, and myalgia have been reported. Particularly, hypomagnesemia may occur, so magnesium levels should be checked regularly if used for a long time. This medication suppresses stomach acid, which may slightly increase the risk of bacterial infections in the gastrointestinal tract. Additionally, long-term high-dose use may increase the risk of fractures, so caution is needed for patients with osteoporosis. This medication may interact with other drugs, so particularly when used in combination with anticoagulants, antibiotics, antiviral agents, and anticonvulsants, a consultation with a doctor is advised. Data regarding use during pregnancy is limited, so it should be administered cautiously to pregnant women, and it is recommended not to use this medication while breastfeeding. In cases of overdose, there is no specific antidote, and treatment should be symptomatic, as this medication is not removed by dialysis. Lastly, this medication should be kept out of reach of children and should not be transferred to other containers.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disorders, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, xerostomia, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, mucosal membrane syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal bloating, allergic reaction, back pain, chest pain, sternal pain, facial edema, facial flushing, fatigue, fever, influenza-like illness, generalized edema, leg edema, malaise, pain, stiffness, peripheral edema, flushing, hypertension, tachycardia, thyroid gland enlargement, irritable bowel syndrome, worsening of constipation, dyspepsia, dysphagia, gastrointestinal malformation, epigastric pain, belching, esophageal disorders, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased serum gastrin levels, tongue disorders, tongue edema, ulcerative stomatitis, ear pain, tinnitus, anemia, hypopigmented anemia, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, abnormal liver function, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, thirst, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, seizures, fibromyalgia syndrome, hernia, polymyalgia rheumatica, loss of appetite, apathy, increased appetite, confusion, worsening of depression, hypertonia, sensory loss, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disorders, tremors, visual field defect, dysmenorrhea, menstrual disorders, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papular rash, otitis media, olfactory abnormalities, taste loss, taste distortion, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, urinary frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyps or nodules, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, gastric fundus polyps, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture, at room temperature between 1 to 30 degrees Celsius. This helps maintain the medication's efficacy and safety.

Appearance and packaging

Appearance

Pale pink round film-coated tablet

Package unit

28 tablets (14 tablets/PTP) x 2

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.